Restless Legs Syndrome Market

Market Overview:

The 7 major restless legs syndrome markets are expected to exhibit a CAGR of 2.49% during 2024-2034.

The restless legs syndrome market has been comprehensively analyzed in IMARC's new report titled "Restless Legs Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Restless legs syndrome refers to a neurological disorder characterized by uncomfortable sensations in the legs, leading to an irresistible urge to move them. These sensations generally range from mild to severe and can interfere with sleep as well as daily activities. In addition to the impulse to move the legs, some people might experience involuntary leg movements during sleep, known as periodic limb movements of sleep (PLMS). The symptoms of the ailment may worsen in the evening or at night and might be exacerbated by stress, anxiety, or prolonged sitting or standing. Diagnosing restless legs syndrome can be challenging since there is no single test that can definitively confirm the condition. However, a diagnosis of the disorder is typically based on a combination of medical history and clinical indications. Doctors will ask about the patient's symptoms, including the nature and frequency of leg sensations, as well as any family history of the condition. In some cases, they may recommend blood tests to check for iron deficiency, which has been associated with an increased risk of the ailment.

The rising cases of dopamine dysfunction, which causes muscle spasms and involuntary movements, are primarily driving the restless legs syndrome market. In addition to this, the increasing prevalence of various associated risk factors, such as peripheral neuropathy, iron deficiency, spinal cord disorders, sleep deprivation, excessive alcohol consumption, etc., is also bolstering the market growth. Moreover, the widespread adoption of benzodiazepines, including clonazepam and diazepam, to help improve sleep quality and provide symptom relief in patients is acting as another significant growth-inducing factor. Besides this, the inflating demand for anticonvulsants that aid in reducing the sensory and motor symptoms of the ailment, such as the uncomfortable sensations accompanying the condition, is also creating a positive outlook for the market. Additionally, the emerging popularity of non-pharmacological treatments, including exercise, massage, stretching, etc., since they improve circulation, reduce stress, and promote relaxation, which can all contribute to enhancing sleep quality, is augmenting the market growth. Furthermore, the escalating utilization of neuroimaging techniques, such as functional magnetic resonance imaging (fMRI), to identify regions of the brain that are involved in the sensation of leg discomfort and the urge to move the legs is expected to drive the restless legs syndrome market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the restless legs syndrome market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for restless legs syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the restless legs syndrome market in any manner.

Key Highlights:

• Restless legs syndrome affects 5% to 15% of the U.S. population.
• Although restless legs syndrome becomes more common with age, it can appear in children.
• Approximately 33-40% of patients with severe restless legs syndrome experience their first symptoms before the age of 20.
• Women are affected more commonly than men, in a ratio of almost 2:1.
• Restless legs syndrome affects African Americans less frequently than white individuals.

Drugs:

Requip (Ropinirole) is a medicine that treats restless legs syndrome. It is consumed orally. Ropinirole functions as a D2, D3, and D4 dopamine receptor agonist, having the highest affinity for D3, which is predominantly present in the limbic areas

Mirapex (Pramipexole) tablets are used to treat moderate-to-severe primary restless leg syndrome. It can be taken orally with or without food. The recommended initial dose for MIRAPEX tablets is 0.125 mg, given once daily, 2-3 hours before bedtime.

Injectafer, which contains ferric carboxymaltose, is an injectable iron supplement that can be utilized for the treatment of moderate to severe restless leg syndrome. It is the first-line treatment for restless leg syndrome patients with low serum ferritin levels or iron insufficiency.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the restless legs syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the restless legs syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current restless legs syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the restless legs syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the restless legs syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the restless legs syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of restless legs syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of restless legs syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of restless legs syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with restless legs syndrome across the seven major markets?
• What is the size of the restless legs syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of restless legs syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Restless Legs Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for restless legs syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the restless legs syndrome market?
• What are the key regulatory events related to the restless legs syndrome market?
• What is the structure of clinical trial landscape by status related to the restless legs syndrome market?
• What is the structure of clinical trial landscape by phase related to the restless legs syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the restless legs syndrome market?